Ignore the FDA and buy Acrux, page-21

The new dude:
Michael Kotsanis has over 20 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He is the Chief Commercial Officer for Synthon, a position he has held since mid 2010. Synthon is a fast growing specialty pharmaceutical company based in The Netherlands and is a leader in the field of generic medicines. Synthon employs over 1400 people in 11 countries. At Synthon he is responsible for developing and expanding its global business operations leveraging the company's world class product portfolio and R&D capabilities. Until mid 2010, he served as President, Europe, Middle East and Africa for Hospira, where he was responsible for developing strategy, delivering growth and attaining market leadership in the EMEA region. Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he served as President, Asia-Pacific.From 2002 he had responsibility for leading Mayne's commercial and technical operations and associated activities across the Asia Pacific region. He joined Mayne following their acquisition of F H Faulding Pharmaceuticals in 2001, where he held responsibility for sales and marketing strategy and execution in Australia and New Zealand. Prior to Faulding, Kotsanis began his career with Boehringer Ingelheim where he held a variety of sales and marketing positions over an 11 year period. Kotsanis earned a bachelor of science degree from Monash University, Melbourne and a master's degree in business from the University of Technology, Sydney.

Background of MK almost exclusively in generics suggests he might aim to use his contacts to translate generics into Axiron applicator or Evamist spray format. Given that the Hexima collaboration formed the basis of the fungal/NMSC 'pipeline products' which now seems to be in doubt (PR 21Aug14), and this slide shows a big gap between new and approved products: http://www.acrux.com.au/irm/content/product-portfolio.aspx?RID=280, his background looks applicable hopefully to accelerate new product development.